Predictive index for tumor immunotherapy

• Main Authors: WANG YUQI, YANG LING, ZHANG CHUNLIU, XU YAPING, GUAN YANFANG, LI JIN, YI XIN
• Format: Patent
• Language: Chinese; English
• Published: 04.12.2020
• Subjects: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The invention discloses a method and system for predicting the immunotherapy effect of a PD-1/PD-L1 inhibitor. The method comprises the following steps of acquiring the types and abundance of T cell receptors of tumor infiltrating lymphocytes of a subject and the types of T cell receptors of CD8+PD1+T cells of baseline peripheral blood; counting the types of common T cell receptors of the tumor infiltrating lymphocytes and the CD8+PD1+T cells of the subject, and calculating the average proportion of the tumor infiltrating lymphocytes with the common T cell receptors in the tumor infiltrating lymphocytes to serve as an IR index; and judging the immunotherapy effect of the PD-1/PD-L1 inhibitor according to the IR index. The method provided by the invention can provide the predictive index ofthe tumor immunotherapy effect and prognosis, and can effectively screen immunotherapy response patient groups. 本发明公开了一种PD-1/PD-L1抑制剂免疫治疗疗效预测的方法和系统。所述方法包括：获取受试者的肿瘤浸润淋巴细胞的T细胞受体的种类和丰度，以及基线外周血的CD8+PD1+ T细胞的T细胞受体的种类；统计受试者的肿瘤浸润淋巴